KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Liabilities and Shareholders Equity (2016 - 2025)

Alnylam Pharmaceuticals' Liabilities and Shareholders Equity history spans 17 years, with the latest figure at $5.0 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 17.13% year-over-year to $5.0 billion; the TTM value through Dec 2025 reached $18.6 billion, up 14.24%, while the annual FY2025 figure was $5.0 billion, 17.13% up from the prior year.
  • Liabilities and Shareholders Equity reached $5.0 billion in Q4 2025 per ALNY's latest filing, up from $4.9 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $5.0 billion in Q4 2025 to a low of $3.3 billion in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $3.9 billion, with a median of $3.7 billion recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 42.8% in 2021, then decreased 5.1% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.6 billion in 2021, then decreased by 2.66% to $3.5 billion in 2022, then increased by 7.99% to $3.8 billion in 2023, then rose by 10.71% to $4.2 billion in 2024, then rose by 17.13% to $5.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Liabilities and Shareholders Equity are $5.0 billion (Q4 2025), $4.9 billion (Q3 2025), and $4.6 billion (Q2 2025).